Stockscreener 앱 받기
158.76
1.01%
1.71
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com Nigeria
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead - Sahm
Novartis' Strong Innovation Supports Industry-Leading Margins - morningstar.com
Novartis stock hits all-time high at 153.83 USD By Investing.com - Investing.com Australia
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead - Benzinga
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales - Finviz
Novartis stock hits all-time high at 153.83 USD - Investing.com
Earnings call transcript: Novartis Q4 2025 earnings beat forecasts, stock jumps - Investing.com
Peering Into Novartis AG's Recent Short Interest - Sahm
Why Analysts Are Closely Watching Novartis AG (NVS) - Finviz
Jim Cramer is Optimistic About Novartis' (NVS) Cancer Drug - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Novartis Positions US Strategy As Defense Against Rising Trade Levies - Sahm
Novartis stock hits all-time high at $146.4 By Investing.com - Investing.com South Africa
Novartis stock hits all-time high at $146.4 - Investing.com
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals - Chartmill
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Novartis ADR: Defensive Giant Tests Investor Patience As Rally Cools - AD HOC NEWS
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case - Chartmill
Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub - Finviz
The Truth About Novartis AG (ADR): Why Everyone Is Suddenly Watching This Pharma Giant - AD HOC NEWS
Is Novartis AG Gaining or Losing Market Support? - Sahm
3 Dividend Stocks to Buy in 2026 and Hold Forever - Finviz
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Sahm
New Investors: 3 Stocks to Build Your Portfolio Around in 2026 - Finviz
The Truth About Novartis AG (ADR): Is Wall Street’s Quiet Giant Your Next Power Play? - AD HOC NEWS
The Truth About Novartis AG: Is This Pharma Giant a Silent Stock Cheat Code? - AD HOC NEWS
Novartis AG (ADR): Quiet Confidence Or Complacency? A Deep Look At NVS After A Steady Climb - AD HOC NEWS
Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals - Chartmill
7 Newly Overvalued Stocks this Week - Morningstar
EBITDA per share of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView — Track All Markets
NVS Price History for Novartis Ag ADR Stock - Barchart.com
2 Top Stocks to Buy and Hold for the Long Term - Finviz
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts - Sahm
Pharma's $370B Bet on America: The ETF Plays for 2026 - Barchart.com
White House Readies Drug Price Deals With AbbVie, Novartis, Roche - Sahm
Novartis, Roche to reach drug pricing deal with White HouseBloomberg - Investing.com
HSBC Lifts PT on Novartis AG (NVS) to $112 From $106 - Finviz
2.94%
0.08%
자본화:
|
볼륨(24시간):